Advanced in CHST3-Related Skeletal Dysplasia

Genevieve Baujat

Paris, FR

Advanced in CHST3-Related Skeletal Dysplasia

Paris, FR

OverviewLocationsClinical Research

Overview

Genevieve Baujat practices in Paris, France. Ms. Baujat is rated as an Advanced expert by MediFind in the treatment of CHST3-Related Skeletal Dysplasia. Her top areas of expertise are Fibrodysplasia Ossificans Progressiva, Brachydactyly Mononen Type, Acromicric Dysplasia, Acromesomelic Dysplasia Campailla Martinelli Type, and Adenoidectomy.

Her clinical research consists of co-authoring 154 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of CHST3-Related Skeletal Dysplasia.

Gender

Female

Locations

Paris, France

Other Locations

France

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

7 Clinical Trials

A Phase 2, Open-Label Extension, Efficacy and Safety Study of a Retinoic Acid Receptor Gamma (RARγ) Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Enrollment Status: Completed

Publish Date: February 19, 2025

Intervention Type: Drug

Study Drug: Palovarotene

Study Phase: Phase 2

A Phase 3, Efficacy and Safety Study of Oral Palovarotene for the Treatment of Fibrodysplasia Ossificans Progressiva (FOP)

Enrollment Status: Completed

Publish Date: November 29, 2023

Intervention Type: Drug

Study Drug: Palovarotene

Study Phase: Phase 3

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of Palovarotene in Subjects With Multiple Osteochondromas

Enrollment Status: Terminated

Publish Date: August 01, 2022

Intervention Type: Other, Drug

Study Phase: Phase 2

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study of a RARγ-Specific Agonist (Palovarotene) in the Treatment of Preosseous Flare-ups in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Enrollment Status: Completed

Publish Date: February 16, 2021

Intervention Type: Drug

Study Phase: Phase 2

A Phase 2, In-Home, Safety and Efficacy Evaluation of Episodic Administration of Open-Label Palovarotene in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Enrollment Status: Terminated

Publish Date: October 19, 2020

Intervention Type: Drug

Study Phase: Phase 2

A Natural History, Non-Interventional, Two-Part Study in Subjects With Fibrodysplasia Ossificans Progressiva (FOP)

Enrollment Status: Completed

Publish Date: June 26, 2020

Non-randomised Open Label Pilot Study of Sirolimus Therapy for Segmental Overgrowth Due to PIK3CA- Related Overgrowth

Enrollment Status: Completed

Publish Date: October 02, 2018

Intervention Type: Drug

Study Phase: Phase 2

View 6 Less Clinical Trials

154 Total Publications

TYRA-300, an FGFR3 selective inhibitor, promotes bone growth in two FGFR3-driven models of chondrodysplasia.

Journal: JCI insight

Published: April 03, 2025

View All 154 Publications

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Baujat's expertise for a condition

ConditionClose